X4 Pharmaceuticals To Present At ASH 2024 On Mavorixafor For Chronic Neutropenia

ARS Pharmaceuticals, Inc. is a biopharmaceutical company focused on empowering patients and carers to manage severe allergic reactions. Today, we announced the upcoming launch of the Neffy in Schools Program in January 2025. This initiative offers public and private K-12 schools in the U.S. the opportunity to receive two cartons (four single-use doses) of neffy® (epinephrine nasal spray) 2mg for free to use in emergencies. The product was recently approved for treating Type I Allergic Reactions, including anaphylaxis, in adults and children weighing 30 kg (66 lbs.) or more. Schools participating in the program can also request replacement doses as needed.

Type I allergic reactions, which can occur rapidly and become life-threatening, are triggered by insect stings, foods, medications, exercise, or unknown causes. Research indicates up to 18% of children with food allergies experience accidental exposure at school, and 25% of severe reactions in schools involve children with no prior food allergy diagnosis.

Richard Lowenthal, Co-Founder, President, and CEO of ARS Pharmaceuticals, said in a statement, “The potential for severe allergic reactions to food, medication, exercise, or insect bites can quickly result in an emergency if epinephrine is not available. Since many unexpected allergic reactions happen during the school day, readily available epinephrine is crucial. Additionally, many people, including students, have a fear of needles, which could impact, delay, or prevent the use of an auto-injector.

He further commented, “We are committed to making neffy, the only needle-free epinephrine treatment option, available free of charge to all eligible schools through our neffy in Schools program because we know neffy will save lives. We also understand that there are currently many challenges for schools that stock epinephrine. neffy is safer for school staff when administering epinephrine in allergy emergency situations; it is easier to dispose of as neffy doesn’t contain any sharps, and it has a long shelf life of 30 months.”

Schools are encouraged to review their state’s legislation to ensure Neffy meets local requirements for stocking epinephrine and provides legal protection for its use. Currently, 49 states and Washington, D.C., allow schools to stock epinephrine, but some may need updates to include neffy and its nasal administration method. School administrators in states requiring updates may need to contact legislators to revise laws to include FDA-approved epinephrine products like neffy.

Ahead of the program’s launch, ARS Pharmaceuticals will host a webinar on December 12 to inform school nurses and administrators about the neffyinSchools Program, product details, training, and online resources. Application instructions for schools requesting nNeffy 2 g will be available in January 2025.